These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 21374317)

  • 21. CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization.
    Encke J; zu Putlitz J; Stremmel W; Wands JR
    Arch Virol; 2003 Mar; 148(3):435-48. PubMed ID: 12607097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA.
    Lee KW; Jung J; Lee Y; Kim TY; Choi SY; Park J; Kim DS; Kwon HJ
    Mol Immunol; 2006 May; 43(13):2107-18. PubMed ID: 16442622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [CpG motif and tuberculosis immunity].
    Yamamoto S
    Kekkaku; 2010 Jun; 85(6):515-22. PubMed ID: 20662247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
    Jakob T; Walker PS; Krieg AM; Udey MC; Vogel JC
    J Immunol; 1998 Sep; 161(6):3042-9. PubMed ID: 9743369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapeutic applications of CpG-containing oligodeoxynucleotides.
    Klinman DM; Ishii KJ; Gursel M; Gursel I; Takeshita S; Takeshita F
    Drug News Perspect; 2000 Jun; 13(5):289-96. PubMed ID: 12937643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
    Ishii KJ; Gursel I; Gursel M; Klinman DM
    Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
    Zhang Z; Guo K; Schluesener HJ
    J Neuroimmunol; 2005 Apr; 161(1-2):68-77. PubMed ID: 15748945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CpG motifs in bacterial DNA trigger direct B-cell activation.
    Krieg AM; Yi AK; Matson S; Waldschmidt TJ; Bishop GA; Teasdale R; Koretzky GA; Klinman DM
    Nature; 1995 Apr; 374(6522):546-9. PubMed ID: 7700380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
    Sen G; Flora M; Chattopadhyay G; Klinman DM; Lees A; Mond JJ; Snapper CM
    Cell Immunol; 2004; 232(1-2):64-74. PubMed ID: 15922717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TLR9 and the recognition of self and non-self nucleic acids.
    Lamphier MS; Sirois CM; Verma A; Golenbock DT; Latz E
    Ann N Y Acad Sci; 2006 Oct; 1082():31-43. PubMed ID: 17145922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How BCG led to the discovery of immunostimulatory DNA.
    Tokunaga T; Yamamoto T; Yamamoto S
    Jpn J Infect Dis; 1999 Feb; 52(1):1-11. PubMed ID: 10808252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines.
    Rieger R; Kipps TJ
    Cancer Res; 2003 Jul; 63(14):4128-35. PubMed ID: 12874017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex.
    Jones DE; Palmer JM; Burt AD; Walker C; Robe AJ; Kirby JA
    Hepatology; 2002 Sep; 36(3):679-86. PubMed ID: 12198661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators.
    Dorn A; Kippenberger S
    Curr Opin Mol Ther; 2008 Feb; 10(1):10-20. PubMed ID: 18228177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction of a recombinant plasmid containing multi-copy CpG motifs and its effects on the innate immune responses of aquatic animals.
    Chen Y; Xiang LX; Shao JZ
    Fish Shellfish Immunol; 2007 Sep; 23(3):589-600. PubMed ID: 17475508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant properties of CpG oligonucleotides in primates.
    Verthelyi D
    Methods Mol Med; 2006; 127():139-58. PubMed ID: 16988453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets.
    Linghua Z; Xingshan T; Fengzhen Z
    Vaccine; 2008 Jan; 26(2):224-33. PubMed ID: 18063448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant activity of CpG oligodeoxynucleotides.
    Klinman DM
    Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
    Zimmermann S; Dalpke A; Heeg K
    Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines.
    Lipford GB; Sparwasser T; Bauer M; Zimmermann S; Koch ES; Heeg K; Wagner H
    Eur J Immunol; 1997 Dec; 27(12):3420-6. PubMed ID: 9464831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.